Kaia Health gets $75M on rising interest in its virtual treatments for persistent discomfort and COPD
New York headquartered Kaia Health, which offers AI-assisted digital therapies by means of a mobile app for persistent discomfort related to musculoskeletal (MSK) conditions and for Chronic Obstructive Lung Disease (COPD), has actually raised a $75 million Series C. The round was led by an unnamed leading growth equity fund with support from existing investors, including Optum Ventures, […] In the United States Kaia focuses on activation rate as a percentage of the company population — — and Mehl says this stands between 5%-10%, depending on how the app is interacted to possible users. In February it kicked off a major combination of its patient-facing MSK therapy/pain-management app with a referral system that plugs into services used by other health care providers — — using an escalation algorithm and screening and triage system, which it calls Kaia Entrance — — to recognize clients at threat of needing more intrusive or extreme treatment than the digital treatments its app can supply. “And also work with external medical companies — — physicians etc — and bring our users at the best point to the best physician to avoid any degeneration in pain that we can not deal with in the app. While, for Kaia, it’s deeply focused on building tech to deal with a few specific illness — and so, also, isn’t best suited to basic medical service shipment. …
Recent Comments